Gene editing company CRISPR Therapeutics and cell-based medicines and life sciences firm MaxCyte have expanded clinical and commercial license agreement into oncology.
{iframe}https://www.pharmaceutical-business-review.com/news/crispr-maxcyte-expand-partnership-to-develop-immuno-oncology-therapies/{/iframe}